A detailed history of Interchange Capital Partners, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Interchange Capital Partners, LLC holds 600 shares of CRSP stock, worth $28,380. This represents 0.01% of its overall portfolio holdings.

Number of Shares
600
Previous 600 -0.0%
Holding current value
$28,380
Previous $32,000 12.5%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$44.62 - $62.75 $23,737 - $33,383
-532 Reduced 6.09%
8,209 $385,000
Q2 2024

Jul 31, 2024

BUY
$51.17 - $68.18 $82,690 - $110,178
1,616 Added 22.68%
8,741 $472,000
Q1 2024

May 08, 2024

BUY
$60.67 - $89.12 $30,638 - $45,005
505 Added 7.63%
7,125 $485,000
Q4 2023

Jan 09, 2024

BUY
$38.62 - $72.18 $33,020 - $61,713
855 Added 14.83%
6,620 $414,000
Q3 2023

Nov 13, 2023

BUY
$45.39 - $59.0 $14,978 - $19,470
330 Added 6.07%
5,765 $261,000
Q2 2023

Aug 08, 2023

BUY
$43.47 - $67.77 $26,386 - $41,136
607 Added 12.57%
5,435 $305,000
Q1 2023

May 15, 2023

BUY
$41.0 - $56.12 $197,948 - $270,947
4,828 New
4,828 $218,000
Q3 2022

Nov 07, 2022

SELL
$61.1 - $83.78 $106,802 - $146,447
-1,748 Reduced 23.43%
5,714 $373,000
Q2 2022

Aug 05, 2022

BUY
$43.23 - $73.83 $5,230 - $8,933
121 Added 1.65%
7,462 $453,000
Q1 2022

May 13, 2022

BUY
$53.19 - $79.24 $56,328 - $83,915
1,059 Added 16.86%
7,341 $460,000
Q4 2021

Feb 04, 2022

BUY
$70.09 - $111.29 $440,305 - $699,123
6,282 New
6,282 $476,000
Q2 2021

Aug 16, 2021

SELL
$100.84 - $161.89 $763,157 - $1.23 Million
-7,568 Closed
0 $0
Q1 2021

May 05, 2021

SELL
$110.72 - $210.04 $241,923 - $458,937
-2,185 Reduced 22.4%
7,568 $1.01 Million
Q4 2020

Feb 16, 2021

BUY
$79.67 - $173.23 $777,021 - $1.69 Million
9,753 New
9,753 $1.49 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.69B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Interchange Capital Partners, LLC Portfolio

Follow Interchange Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Interchange Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Interchange Capital Partners, LLC with notifications on news.